Inflammatory Bowel Disease Clinical Trial
Official title:
A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis
The goal of this study is to assess if oral vancomycin can restore the normal bile acid metabolism of people with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease. Study participants will provide blood and stool samples in order to evaluate the bile acid metabolism before a short course of vancomycin and then again after to assess for change. The investigators will also assess the blood and stool of healthy people, and people with IBD (without PSC) as a control group.
Primary Sclerosing Cholangitis (PSC) is a chronic inflammatory and fibrotic disease of the
intra and extrahepatic ducts of unknown etiology that predominately occurs in people with
Inflammatory Bowel Disease (IBD). One hypothesis is that altered microbiome (bacteria in the
gut) in people with IBD are responsible for the inflammation in the liver seen in PSC. Bile
acids (BAs) represent a unique mechanism of communication between the host and intestinal
microbiome and the liver. Synthesized in the liver, bile acids are metabolized by intestinal
bacteria hydroxylases to secondary BAs which then re-enter the portal circulation. Altered
metabolism of BAs has been associated with gallstones and colorectal cancer and is
hypothesized to play a role in the inflammatory response of certain disease such as IBD and
PSC.
IBD has been associated with impairment of bile acid (BA) metabolism. In addition BAs play a
role in regulating bacterial growth of the intestine and thus have an effect on the integrity
of the intestinal mucosa, which is an essential component of IBD. Perturbations in this
system could increase bacterial translocation into the portal system due to loss of
protective mucosal factors or bacterial overgrowth.
The overall goal of this study is to assess the changes in BAs metabolism following
administration of oral vancomycin. The investigators will also describe the relationship of
the intestinal microbiome and BA metabolism in PSC/IBD.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03278912 -
Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations
|
||
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05579392 -
A Randomized Crossover Trial of Bright Light Therapy in Crohn's Disease on Intestinal Barrier Homeostasis
|
N/A | |
Completed |
NCT03264690 -
Study to Observe the Change in Microbiome in Human Derived Sample and the Relation With Clinical Response Before and After the Anti-TNF Treatment in IBD Patients
|
||
Recruiting |
NCT02861053 -
Inflammatory Bowel Disease : Could a Regular Physical Activity Reduce Patients Fatigue ?
|
N/A | |
Recruiting |
NCT02275676 -
Resting Energy Expenditure and Nutritional Status in IBD
|
N/A | |
Completed |
NCT02197780 -
Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
|
N/A | |
Completed |
NCT02503696 -
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
|
N/A | |
Completed |
NCT02161640 -
Vascular Dysfunction in Paediatric IBD
|
N/A | |
Completed |
NCT01933867 -
Water-aided Colonoscopy in Inflammatory Bowel Disease Patients
|
N/A | |
Completed |
NCT01852760 -
Assessment of Disease Activity in Ulcerative Colitis by Endoscopic Ultrasound
|
N/A | |
Completed |
NCT01860651 -
Web-based Monitoring in Children and Adolescents With Inflammatory Bowel Disease
|
N/A | |
Completed |
NCT01692743 -
Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)
|
Phase 3 | |
Completed |
NCT01688557 -
Trial on Innovative Technologies in Colonoscopy
|
N/A | |
Completed |
NCT01676324 -
FOCUS: The Future of Fecal Calprotectin Utility Study for the Diagnosis and Management of Inflammatory Bowel Disease (IBD)
|
N/A | |
Completed |
NCT01666535 -
Infliximab IBD Influenza Vaccine Study
|
N/A | |
Completed |
NCT01981616 -
Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab
|
Phase 1 | |
Completed |
NCT01557387 -
Real-time Diagnosis of Pseudopolyps During Colonoscopy
|
||
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT01221818 -
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects
|
Phase 1 |